Trevi Therapeutics
TRVI
19 hedge funds and large institutions have $35.6M invested in Trevi Therapeutics in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 3 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
12% more capital invested
Capital invested by funds: $31.7M → $35.6M (+$3.84M)
6% more funds holding
Funds holding: 18 → 19 (+1)
4.83% less ownership
Funds ownership: 70.77% → 65.94% (-4.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$282K |
| 2 |
WA
WealthTrust Axiom
Wayne,
Pennsylvania
|
+$79.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$31.1K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$28.1K |
| 5 |
BlackRock
New York
|
+$27.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$36K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$36K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$11.7K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$2K |
| 5 |
First Manhattan
New York
|
-$293 |
TRVI Hedge Fund Activity: Q1 2021 in Review
19 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q1 2021, worth a combined $35.6M — up 12% from $31.7M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new TRVI positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $282K. The largest seller was Canada Pension Plan Investment Board, exiting entirely with an estimated $36K sold.
- 19 institutional investors held Trevi Therapeutics (TRVI) as of Q1 2021, up from 18 in Q4 2020.
- Funds reported $35.6M of Trevi Therapeutics stock for Q1 2021, up 12% quarter-over-quarter.
- 4 funds opened new Trevi Therapeutics positions in Q1 2021 and 3 closed out, a net change of +1 holder.
- The largest Trevi Therapeutics buyer in Q1 2021 was Renaissance Technologies, an estimated $282K added.
- The largest Trevi Therapeutics seller in Q1 2021 was Canada Pension Plan Investment Board, an estimated $36K sold.
Based on aggregated 13F filings for Q1 2021.